
Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.

Diagnoly helps clinicians improve prenatal screening by providing real‑time AI analysis of fetal ultrasound to detect abnormalities and ensure complete exams. It builds Fetoly, a DeepTech B2B SaaS and medical device that uses AI and deep learning models integrated with ultrasound systems to provide on‑device, real‑time feedback during scans. Fetoly analyzes anatomical landmarks, detects over 100 fetal abnormalities, validates exam completeness against ISUOG guidelines, and automates repetitive measurements to increase consistency. The solution runs locally on mobile devices and remains compatible with major ultrasound platforms without requiring cloud services, preserving clinical data control. Diagnoly targets obstetricians and healthcare providers and holds FDA clearance for Fetoly‑Heart and CE marking for fetal heart and brain analysis.
Product: Fetoly — on-device, real-time AI for fetal ultrasound quality assurance and landmark/abnormality detection
Regulatory: FDA clearance for Fetoly-Heart and CE marking for fetal heart and brain analysis
Business model: DeepTech B2B SaaS / medical device targeting obstetricians and healthcare providers
Funding: Seed round Apr 8, 2025 — €5.5M
HQ: Lyon, France
Prenatal screening quality assurance and fetal abnormality detection during obstetric ultrasound
2020
Medical Equipment Manufacturing
€5.5M
Seed round announced to accelerate development of AI prenatal-screening technology; participation from XAnge and existing investors including Les Business Angels des Grandes Écoles (BAdGE)
USD 7,048,095
“Includes participation from Mutuelles Impact, Newfund, XAnge, Les Business Angels des Grandes Écoles, BADGE and other angel / impact investors”
| Company |
|---|